Current collaborations
Antisoma has a successful track record of partnerships for both
in-licensing and out-licensing cancer drugs.
Current collaborations include the following:
Novartis
Worldwide rights to Antisoma's Tumour-Vascular Disrupting Agent
ASA404 are licensed to Novartis.
Merck Serono
Antisoma has licensed exclusive rights for the BC1-IL12 fusion
protein (AS1409).
Cancer Research Technology, UK
Antisoma has an exclusive license for anti-MUC1, humanised HMFG1
(AS1402).
Cancer Research Technology/University of Auckland, New
Zealand
Antisoma has exclusively licensed rights to ASA404.
Institute of Cancer Research (ICR)
Antisoma has a research collaboration with ICR and an exclusive
license to a PPM1D inhibitor programme.
Back to top